---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-059454"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:36:18.656562+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics Q1 net loss $7.5M; advances AJ201 and IV Tramadol programs

## Summary
- Net loss of $7.5M ($1.37 per share) vs $2.9M loss ($2.05 per share) in Q1 2022.
- Cash and equivalents $8.2M at March 31, 2023, up from $6.7M at December 31, 2022.
- R&D expenses $1.2M plus $4.2M in licenses acquired (AJ201) vs $1.8M prior-year period.
- Entered exclusive license for AJ201 (SBMA treatment); Phase 1b/2a trial ongoing; FDA orphan drug designation.
- FDA agreed on most aspects of IV Tramadol safety confirmatory trial protocol; pending final statistical analysis plan.

## SEC filing metadata
- accession: 0001104659-23-059454
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465923059454/0001104659-23-059454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465923059454/tm2315281d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-059454
- JSON: https://secwatch.observer/filing/0001104659-23-059454.json
- Plain text: https://secwatch.observer/filing/0001104659-23-059454.txt

## Key facts
- Earnings Releases
  AVENUE THERAPEUTICS, INC. reported the first quarter ended March 31, 2023 results: net income $7.5 million, or $1.37 per share, EPS $1.37 per share.
  - Period: the first quarter ended March 31, 2023
  - Net income: $7.5 million, or $1.37 per share
  - EPS: $1.37 per share
  - Result: reported results
  source text: Net loss attributable to common stockholders for the first quarter of 2023 was $7.5 million, or $1.37 per share, compared to a net loss of $2.9 million, or $2.05 per share, for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465923059454/0001104659-23-059454-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.